The CAR-T Therapy Shift: Redefining Second-Line Treatment Strategies in Multiple Myeloma

home / meeting-of-the-minds / the-car-t-therapy-shift-redefining-second-line-treatment-strategies-in-multiple-myeloma

Meeting of the Minds video series features an actor portrayal of a hypothetical patient profile developed for educational purposes by leading oncology experts, based on characteristics of patients with various cancer types as seen in clinical practice.

Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP. 1: Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

December 20th 2024

This video episode follows the journey of a 55-year-old female tech CEO with multiple myeloma, highlighting her treatments, relapse challenges, and transition to ide-cel, supported by her active lifestyle and strong support network.

Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

EP. 2: Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

December 20th 2024

Medical experts examine the factors that make Sarah an ideal candidate for CAR-T therapy in the second-line setting, focusing on how her age, fitness, and early relapse influence treatment decisions and exploring alternative options.

Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

EP. 3: Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

January 31st 2025

This video episode explores data supporting ide-cel in the second-line setting for multiple myeloma, highlighting key findings from the KarMMa and KarMMa-3 trials, comparisons to other options, and clinical experiences regarding efficacy, quality of life benefits, and implementation challenges.

4 experts are featured in this series.

EP. 4: Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

January 31st 2025

This video episode examines decision-making between CAR-T therapy and novel agents in the second-line setting, scenarios for preferring alternative therapies, and treatment strategies following progression after ide-cel, emphasizing the impact of prior CAR-T therapy on subsequent choices.